Helicobacter pylori eradication does not influence gastroesophageal reflux disease: A prospective, parallel, randomized, open-label, controlled trial;Erradicação do helicobacter pylori não influencia a doença do refluxo gastroesofágico: Estudo prospectivo, paralelo, randomizado, aberto e controlado

Arquivos de Gastroenterologia

Volumn 49, Issue 1, 2012, Pages 56-63

  Rodrigues, Lino ^a   de Faria, Cintya Miler ^a   Geocze, Stephan ^a   Chehter, Luiz ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Gastroesophageal reflux; Helicobacter infections

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOSCOPY; ERADICATION THERAPY; ESOPHAGUS PH; EVALUATION; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; LOWER ESOPHAGUS SPHINCTER PRESSURE; MALE; MANOMETRY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 84859477015     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/s0004-28032012000100010     Document Type: Article

References (38)

1. Allescher HD, Stoschus B, Wünsch E, Schusdziarra V, Classen M. Effect of human gastrin-17 with and without acid suppression on human esophageal motility. Z Gastroenterol. 1995;33:385-91.
2. Bortolotti M, Pandolfo N, La Rovere G, Giovannini M, Miglioli M. Effect of clarithromycin on esophageal motility. Dis Esophagus. 2000;13:231-3.
3. Buckley M, Culhane A, Drumm B, Keane C, Moran AP, O'Connor HJ, Collins J, Kelleher D, McAvinchey D, Sloan J, O'Morain C. Guidelines for the management of Helicobacter pylori-related upper gastrointestinal diseases. Irish Helicobacter Pylori Study Group. Ir J Med Sci. 1996;165:1-11.
4. Cargill G. How can the contribution of intra-abdominal pressure, crural diaphragm, and smooth muscle sphincter be distinguished in LESP and in LES movements? In: Giuli R, editor. O.E.S.O - The esophagogastric junction. Paris: John Libbey Eurotext; 1998. p. 19-23.
5. Chow WH, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA, Perez-Perez GI, Schoenberg JB, Stanford JL, Rotterdam H, West AB, Fraumeni JF Jr. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res. 1998;58:588-90.
6. Dalton CB, Castell DO. Measurements and interpretations. In: Castell DO, Castell JA, editors. Esophageal motility testing. Norwalk, Connecticut: Appleton & Lange; 1994. p. 61-80.
7. Demeester TR, Johnson LF, Joseph GJ, Toscano MS, Hall AW, Skinner DB. Patterns of gastroesophageal reflux in health and disease. Ann Surg. 1976;184:459-70.
8. Dent J. Gastro-oesophageal reflux disease. Digestion. 1998;59:433-45.
9. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161-81.
10. Genta RM, Huberman RM, Graham DY. The gastric cardia in Helicobacter pylori infection. Hum Pathol. 1994;25:915-9.
11. Gisbert JP, Pajares JM, Losa C. Helicobacter pylori and gastroesophageal reflux disease: friends or foes? Hepatogastroenterology. 1999;46:1023-9.
12. Hackelsberger A, Schultze V, Gunther T, et al. H. pylori prevalence in reflux esophagitis - a case-control study [abstract]. Gastroenterology. 1997;112(Suppl):A137.
13. Iwakiri K, Kawami N, Sano H, Tanaka Y, Umezawa M, Kotoyori M, Hoshihara Y, Sakamoto C. Mechanisms of excessive esophageal acid exposure in patients with reflux esophagitis. Dig Dis Sci. 2009;54:1686-92.
14. Kuipers EJ, Uyterlinde AM, Peña AS, Hazenberg HJ, Bloemena E, Lindeman J, Klinkenberg-Knol EC, Meuwissen SG. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995;90:1401-6.
15. Labenz J, Tillenburg B, Peitz U, Idström JP, Verdú EF, Stolte M, Börsch G, Blum AL. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology. 1996;110:725-32.
16. Labenz J, Blum AL, Bayerdörffer E, Meining A, Stolte M, Börsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 1997;112:1442-7.
17. Labenz J, Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut. 1997;41:277-80.
18. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol. 2002;97:2992-7.
19. Malfertheiner P, Mégraud F, O'Morain C, Bell D, Bianchi Porro G, Deltenre M, Forman D, Gasbarrini G, Jaup B, Misiewicz JJ, Pajares J, Quina M, Rauws E. Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol. 1997;9:1-2.
20. Manes G, Esposito P, Lioniello M, Bove A, Mosca S, Balzano A. Manometric and pH-metric features in gastro-oesophageal reflux disease patients with and without Helicobacter pylori infection. Dig Liver Dis. 2000;32:372-7.
21. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311-5.
22. McCallum RW, Walsh JH. Relationship between lower esophageal sphincter pressure and serum gastrin concentration in Zollinger-Ellison syndrome and other clinical settings. Gastroenterology. 1979;76:76-81.
23. McNamara D, O'Morain C. Gastro-oesophageal reflux disease and Helicobacter pylori: an intricate relation. Gut. 1999 Jul;45:I13-7.
24. Mittal RK, Rochester DF, McCallum RW. Sphincteric action of the diaphragm during a relaxed lower esophageal sphincter in humans. Am J Physiol. 1989;256(1 Pt 1):G139-44.
25. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology. 2001;121:1120-6.
26. Newton M, Bryan R, Burnham WR, Kamm MA. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus. Gut. 1997;40:9-13.
27. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994;272:65-9.
28. O'Connor HJ, Cunnane K. Helicobacter pylori and gastro-oesophageal reflux disease - a prospective study. Ir J Med Sci. 1994;163:369-73.
29. Sainz R, Borda F, Domínguez E, Gisbert JP. [Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group]. Rev Esp Enferm Dig. 1999;91:777-84.
30. Sarnelli G, Ierardi E, Grasso R, Verde C, Bottiglieri ME, Nardone G, Budillon G, Cuomo R. Acid exposure and altered acid clearance in GERD patients treated for Helicobacter pylori infection. Dig Liver Dis. 2003;35:151-6.
31. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SGM. H. pylori, GERD and the efficacy of omeprazole therapy [abstract]. Gastroenterology.1997;112(Suppl):A282.
32. Sekiguchi T, Shirota T, Horikoshi T, et al. Helicobacter pylori infection and severity of reflux [abstract]. Gastroenterology. 1996;110(Suppl):A755.
33. Simpson RJ, Graham SM, Florida-James GD, Connaboy C, Clement R, Jackson AS. Perceived exertion and heart rate models for estimating metabolic workload in elite British soldiers performing a backpack load-carriage task. Appl Physiol Nutr Metab. 2010;35:650-6.
34. Tee W, Lambert JR, Dwyer B. Cytotoxin production by Helicobacter pylori from patients with upper gastrointestinal tract diseases. J Clin Microbiol. 1995;33:1203-5.
35. Vakily M, Wu J, Atkinson SN. Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants. J Clin Pharmacol. 2009;49:1447-55.
36. Vicari JJ, Peek RM, Falk GW, Goldblum JR, Easley KA, Schnell J, Perez-Perez GI, Halter SA, Rice TW, Blaser MJ, Richter JE. The seroprevalence of cagA- positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology. 1998;115:50-7.
37. Wu JC, Sung JJ, Ng EK, Go MY, Chan WB, Chan FK, Leung WK, Choi CL, Chung SC. Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: a study from the East. Am J Gastroenterol. 1999;94:1790-4.
38. Zhang W, Wu J, Atkinson SN. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. J Clin Pharmacol. 2009;49:444-54.